Eli Lilly and Company

lilly.com

Lilly is a global health care leader that unites caring with discovery to make life better for people around the world. For more than a century, we have stayed true to a core set of values—excellence, integrity, and respect for people—that guide us in all we do: discovering medicines that meet real needs, improving the understanding and management of disease, and giving back to communities through philanthropy and volunteerism.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

LILLY LAUNCHES DIGITAL HEALTH OPEN INNOVATION CHALLENGE TO HELP TRANSFORM ATOPIC DERMATITIS CARE

Eli Lilly and Company | September 16, 2020

news image

Eli Lilly and Company has launched an open innovation challenge for individuals and teams across the United States to submit inspiring digital health solutions that can help make life better for people living with atopic dermatitis. The challenge, "Transforming Atopic Dermatitis Care: Enhancing Quality of Life and Patient Care for People Living with Inflammatory Skin Diseases," focuses on leveraging digital technologies to enhance care and improve health and well-being for people with ...

Read More

Pharmacy Market

LILLY AND LYCIA THERAPEUTICS ENTER INTO STRATEGIC COLLABORATION TO DISCOVER AND DEVELOP NOVEL LYSOSOMAL TARGETING CHIMERA (LYTAC) DEGRADERS

Eli Lilly and Company | August 25, 2021

news image

Eli Lilly and Company and Lycia Therapeutics, Inc. today announced a multi-year research collaboration and licensing agreement focused on the discovery, development and commercialization of novel targeted therapeutics using Lycia's proprietary lysosomal targeting chimera, or LYTAC, protein degradation technology. Lycia uses its next-generation degradation approach to target the untapped extracellular proteome, including cell surface receptors and secreted proteins. The LYTAC p...

Read More

GROUND-BREAKING COLLABORATION TO OFFER NEW HEART DISEASE DRUG TO NHS PATIENTS

Pharmacy Business | January 14, 2020

news image

The government on Monday announced a collaboration with Novartis to launch a clinical trial for ‘yet to be approved’ drug inclisiran. The drug could benefit thousands of patients at risk of heart disease in coming years. The ground-breaking collaboration includes Novartis, NHS England and the National Institute for Health Research (NIHR) and Oxford University. The Department of Health and Social Care (DHSC) expects this to position the UK as a world-leading destination to develop cut...

Read More

CIVICA RX PARTNERS WITH THERMO FISHER SCIENTIFIC TO DEVELOP AND MANUFACTURE DRUGS WITH A HISTORY OF DRUG SHORTAGES

Business Wire Press Releases | January 16, 2020

news image

Today announced it has signed a long-term agreement with Thermo Fisher Scientific to develop and manufacture medications with Civica as the owner of the regulatory pathway. By working with Thermo Fisher to develop Civica-owned Abbreviated New Drug Applications (ANDAs), Civica will secure the manufacture of certain essential medications, further mitigating the risk of drug shortages in the future. This partnership has an initial seven-year term and represents a key component of Civica’s man...

Read More
news image

LILLY LAUNCHES DIGITAL HEALTH OPEN INNOVATION CHALLENGE TO HELP TRANSFORM ATOPIC DERMATITIS CARE

Eli Lilly and Company | September 16, 2020

Eli Lilly and Company has launched an open innovation challenge for individuals and teams across the United States to submit inspiring digital health solutions that can help make life better for people living with atopic dermatitis. The challenge, "Transforming Atopic Dermatitis Care: Enhancing Quality of Life and Patient Care for People Living with Inflammatory Skin Diseases," focuses on leveraging digital technologies to enhance care and improve health and well-being for people with ...

Read More
news image

Pharmacy Market

LILLY AND LYCIA THERAPEUTICS ENTER INTO STRATEGIC COLLABORATION TO DISCOVER AND DEVELOP NOVEL LYSOSOMAL TARGETING CHIMERA (LYTAC) DEGRADERS

Eli Lilly and Company | August 25, 2021

Eli Lilly and Company and Lycia Therapeutics, Inc. today announced a multi-year research collaboration and licensing agreement focused on the discovery, development and commercialization of novel targeted therapeutics using Lycia's proprietary lysosomal targeting chimera, or LYTAC, protein degradation technology. Lycia uses its next-generation degradation approach to target the untapped extracellular proteome, including cell surface receptors and secreted proteins. The LYTAC p...

Read More
news image

GROUND-BREAKING COLLABORATION TO OFFER NEW HEART DISEASE DRUG TO NHS PATIENTS

Pharmacy Business | January 14, 2020

The government on Monday announced a collaboration with Novartis to launch a clinical trial for ‘yet to be approved’ drug inclisiran. The drug could benefit thousands of patients at risk of heart disease in coming years. The ground-breaking collaboration includes Novartis, NHS England and the National Institute for Health Research (NIHR) and Oxford University. The Department of Health and Social Care (DHSC) expects this to position the UK as a world-leading destination to develop cut...

Read More
news image

CIVICA RX PARTNERS WITH THERMO FISHER SCIENTIFIC TO DEVELOP AND MANUFACTURE DRUGS WITH A HISTORY OF DRUG SHORTAGES

Business Wire Press Releases | January 16, 2020

Today announced it has signed a long-term agreement with Thermo Fisher Scientific to develop and manufacture medications with Civica as the owner of the regulatory pathway. By working with Thermo Fisher to develop Civica-owned Abbreviated New Drug Applications (ANDAs), Civica will secure the manufacture of certain essential medications, further mitigating the risk of drug shortages in the future. This partnership has an initial seven-year term and represents a key component of Civica’s man...

Read More